Exelixis (EXEL) Competitors

Exelixis (NASDAQ:EXEL) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

Does the MarketBeat Community favor EXEL or ALNY?

Alnylam Pharmaceuticals received 538 more outperform votes than Exelixis when rated by MarketBeat users. Likewise, 76.28% of users gave Alnylam Pharmaceuticals an outperform vote while only 68.58% of users gave Exelixis an outperform vote.

Company	Underperform	Outperform
Exelixis	Outperform Votes 620 68.58%	Underperform Votes 284 31.42%
Alnylam Pharmaceuticals	Outperform Votes 1158 76.28%	Underperform Votes 360 23.72%

Does the media refer more to EXEL or ALNY?

In the previous week, Alnylam Pharmaceuticals had 11 more articles in the media than Exelixis. MarketBeat recorded 47 mentions for Alnylam Pharmaceuticals and 36 mentions for Exelixis. Exelixis' average media sentiment score of 1.05 beat Alnylam Pharmaceuticals' score of 0.80 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	20 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	23 Very Positive mention(s)	8 Positive mention(s)	10 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

Do insiders and institutionals hold more shares of EXEL or ALNY?

85.3% of Exelixis shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 2.9% of Exelixis shares are held by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Do analysts prefer EXEL or ALNY?

Exelixis currently has a consensus price target of $37.59, suggesting a potential upside of 2.42%. Alnylam Pharmaceuticals has a consensus price target of $312.30, suggesting a potential upside of 16.33%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	8 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alnylam Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.76

Is EXEL or ALNY more profitable?

Exelixis has a net margin of 24.04% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Exelixis' return on equity of 23.52% beat Alnylam Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	24.04%	23.52%	17.95%
Alnylam Pharmaceuticals	-12.37%	N/A	-6.83%

Which has more volatility & risk, EXEL or ALNY?

Exelixis has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500.

Which has stronger valuation & earnings, EXEL or ALNY?

Exelixis has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.17B	4.74	$521.27M	$1.77	20.73
Alnylam Pharmaceuticals	$2.25B	15.53	-$278.16M	-$2.17	-123.71

Summary

Exelixis and Alnylam Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.